Allan Vaag
71 – 80 of 83
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2009
-
Mark
Sustained Effects of Interleukin-1 Receptor Antagonist Treatment in Type 2 Diabetes
(
- Contribution to journal › Article
- 2008
-
Mark
Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes
(
- Contribution to journal › Article
-
Mark
Sex and muscle structural lipids in obese subjects - an impact on insulin action?
(
- Contribution to journal › Article
-
Mark
Sustained postprandial decrease in plasma levels of LDL cholesterol in patients with type-2 diabetes mellitus
(
- Contribution to journal › Article
-
Mark
Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes
(
- Contribution to journal › Article
- 2007
-
Mark
Targeting hyperglycaemia with either metformin or repaglinide in non-obese patients with type 2 diabetes: results from a randomized crossover trial
(
- Contribution to journal › Article
-
Mark
Non-obese patients with type 2 diabetes and prediabetic subjects: distinct phenotypes requiring special diabetes treatment and (or) prevention?
(
- Contribution to journal › Article
-
Mark
Interleukin-1-receptor antagonist in type 2 diabetes mellitus
(
- Contribution to journal › Article